Johnson & Johnson Reports P-III (MDD3001) Study Data of Seltorexant for Treating Major Depressive Disorder
Shots:
- J&J reported topline results from the P-III (MDD3001) trial assessing the safety & efficacy of seltorexant adj. (20mg, oral, QD) vs PBO, adj. to background SSRI/SNRI for improving depressive symptoms in MDD adults & elderly patients with insomnia symptoms
- The study met all the 1EPs & 2EPs, showing improved depressive symptoms assessed by MADRS total score at D43 and sleep disturbances in patients with moderate-to-severe depression unresponsive to SSRI/SNRI treatment with a safe & well-tolerated profile as well as AEs similar to prior studies. Results being highlighted at the ASCP 2024
- Seltorexant is a FIC therapy that targets human orexin-2 receptor to improve mood and sleep symptoms associated with depression
Ref: Johnson & Johnson| Image: Johnson & Johnson
Related News:- Johnson & Johnson to Acquire Numab's Yellow Jersey Therapeutics for an Aggregate of ~$1.25B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
